I’ve always been interested in innovative ways to treat cancer and obtained a master’s in translational cancer research from King’s College London last year.
My research in PRIMA will aim to improve our understanding on what principles rule T cell recognition of MHC-presented epitopes. I will use viral proteins to induce activation of T cells through TCR recognition, and later sequence these TCRs and validate their functionality. The goal is to gather hundreds of these sequences to train a machine learning algorithm to predict, for any given epitope, a TCR sequence that will be able to recognize it.
Two obligatory questions!
1. What brought you to PRIMA?
I believe incredible things can be done for cancer patients by harnessing the immense power that the immune system holds. Ever since I learned more about immunotherapy in my master’s, I fantasized about being able to do research in this field. PRIMA’s extensive expertise in precision immunotherapy and strong connections with pioneering international scientists in the field motivated me to join the team.
2. What are you passionate about?
I am a very active person, I enjoy running, bouldering, hiking and dancing in my free time. Just three weeks after moving to Norway, I ran the Oslo Halvmaraton and it turned out to be a great way to get to know my new city!
